Virtual Library
Start Your Search
Tatsuya Nishi
Author of
-
+
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 2
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.01-64 - Effect of Amrubicin in Patients with Previously Treated Non-Small-Cell Lung Cancer (Now Available) (ID 599)
08:00 - 18:00 | Author(s): Tatsuya Nishi
- Abstract
Background
Although the prognosis of non-small cell lung cancer (NSCLC) has been rapidly improved due to the appearance of various tyrosine kinase inhibitors and immune checkpoint inhibitors, cytotoxic chemotherapy are still important treatment for patients who can’t receive these drugs or are ineffective for these drugs. Amrubicin (AMR) couldn’t significantly improve the progression free survival compared with docetaxel in a randomized phase III trial of Japanese previously treated NSCLC patients, but median progression free survival (PFS) and overall survival (OS)were comparable in the amrubicin and docetaxel groups. The purpose of this study is to clarify the use of amrubicin in clinical practice.
Method
From January 2014 to March 2019, 479 progressive or recurrent NSCLC patients received chemotherapy or radiotherapy. Only 27 patients received AMR. We retrospectively evaluated these 27 patients.
Result
None of the NSCLC patients who received AMR had epidermal growth factor recepter gene mutations nor anaplastic lymphoma kinase gene translocations. Median number of prior chemotherapy regimens was four, and median PFS was 62 days and OS was 229 days. Overall response rate was 7.4% and disease control rate was 37.0%.
Conclusion
AMR was often used for patients considered to have a poor prognosis, and its effect was limited.
-
+
EP1.01-99 - Effect of Immune Checkpoint Inhibitors Re-Administration in Non-Small-Cell Lung Cancer Patients (Now Available) (ID 236)
08:00 - 18:00 | Author(s): Tatsuya Nishi
- Abstract
Background
Immune checkpoint inhibitors, drugs targeting the programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) pathways, are approved for the treatment of patients with non-small-cell lung cancer (NSCLC) with impressive clinical activity and durable responses in some patients. But the re-administration of immune checkpoint inhibitors have not be clarified.
Method
From December 2015 to December 2018, 93 NSCLC patients received immune checkpoint inhibitor monotherapy. We retrospectively evaluated these 93 patients.
Result
6 patients received re-administration of immune checkpoint inhibitors. Median progression free survival of immune checkpoint inhibitors initial treatment and re-administration were 98 and 55 (p = 0.139). Overall response rate was 24.7% and 0% (p = 0.331) and disease control rate was 53.7% and 16.7% (p = 0.105). There was no significant difference between initial treatment and re-administration. The effect of re-administration of immune checkpoint inhibitor is not so high, but one patient received more than 6months.
Conclusion
The effect of re-administration of immune checkpoint inhibitors are not high, but few patients can receive long term of therapy.
